The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients.
NICE’s draft guidance recommends Kisqali (ribociclib) in combination with fulvestrant for the treatment of locally advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative.
It will be routinely available on the NHS for adults who have had previous endocrine therapy and where exemestane plus everolimus is the most appropriate alternative treatment.
Kisqali is taken as a once-daily pill and belongs to a class of drugs known as cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors.
The drug has been available to patients via the Cancer Drugs Fund (CDF) since 2019, while more evidence was collected to address uncertainties around how much it extends overall survival and its cost-effectiveness.
In a statement, NICE said that the new evidence demonstrates that people receiving Kisqali treatment live longer and experience longer periods before disease progression compared to fulvestrant alone.
“We are pleased therefore that our original decision to make Kisqali available through the CDF not only gave people access to it earlier than would otherwise have been possible, but has now, through the data collected during that time, allowed us to recommend it for routine use on the NHS,” said Meindert Boysen, deputy chief executive and director of the NICE Centre for Health Technology Evaluation.
Following the recommendation for routine NHS funding, Kisqali treatment could now be an option for up to 3,300 women.
This is an auto-generated feed from Pharma Times. Views expressed in this article are of Pharma Times, and Pharma Discoveries is not responsible for any claims made in this story.